Efficacy and tolerance of spironolactone in essential hyperte

DOI: 10.1016/0002-9149(87)91030-7
American Journal of Cardiology, 1987, 60, 820-5.

#	Paper	IF	Citations
230	Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension. *American Journal of Cardiology*, **1988**, 62, 1072-7	3	28
229	Antialdosterones: incidence and prevention of sexual side effects. **1989**, 32, 223-7		68
228	Spironolactone: a re-examination. **1990**, 24, 52-9		8
227	Spironolactone and altizide versus converting enzyme inhibitor (enalapril). *American Journal of Cardiology*, **1990**, 65, 28K-32K	3	1
226	Diuretic drugs. **1990**, 14, 179-187		
225	The Antihypertensive Effect of Spironolactone and Its Effect on Metabolism in Elderly Patients with Essential Hypertension. **1991**, 3, 99-106		
224	Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects. **1991**, 11, 617-39		51
223	Hydrochlorothiazide versus spironolactone: long-term metabolic modifications in patients with essential hypertension. **1991**, 31, 455-61		16
222	Effect of diuretics on the plasma lipid profile. **1992**, 13 Suppl G, 61-7		38
221	Neurohormonal consequences of diuretics in different cardiovascular syndromes. **1992**, 13 Suppl G, 28-33		34
220	Dose-response relationships with antihypertensive drugs. **1992**, 55, 53-93		15
219	Drug-induced disorders of glucose tolerance. **1993**, 118, 529-39		162
218	Primary aldosteronism: difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands. **1994**, 72, 979-84		18
217	Selecting appropriate antihypertensive drug dosages. **1994**, 47, 567-75		5
216	Metabolic Derangements Associated with Diuretic Use. **1997**, 621-636		
215	Effet iatrog□e des m□dicaments □vis□ cardiovasculaire sur la fonction sexuelle □ectile de l'homme. **1998**, 8, 391-404		
214	Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. **1999**, 22, 17-22		60

213	The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. **1999**, 341, 709-17	6637
212	The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. **2000**, 2, 378-83	11
211	Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. **2001**, 37, 677-88	117
210	Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells. **2001**, 76, 153-9	30
209	Aldosterone as a determinant of cardiovascular and renal dysfunction. **2001**, 94, 378-83	45
208	Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. **2001**, 19, 829-42	63
207	A review of the medical treatment of primary aldosteronism. **2001**, 19, 353-61	138
206	Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. **2001**, 38, 1124-9	29
205	Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. **2001**, 37, 801-5	73
204	Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?. **2002**, 4, 441-5	26
203	Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. **2002**, 15, 709-16	293
202	Drugs targeting the renin-angiotensin-aldosterone system. **2002**, 1, 621-36	326
201	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. **2003**, 41, 1148-55	188
200	Primary aldosteronism - treatment options. **2003**, 13 Suppl A, S102-8	22
199	Efficacy of low-dose spironolactone in subjects with resistant hypertension. **2003**, 16, 925-30	383
198	Cardiovascular Agents. **2003**,	
197	Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. **2003**, 18, 1984-92	39
196	Eplerenone: cardiovascular protection. **2003**, 107, 2512-8	118

195	Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. **2003**, 144, 2208-13		293
194	Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). **2003**, 5, 102-18		29
193	The use of selective aldosterone antagonists. **2004**, 6, 342-5		5
192	Hiperaldosteronismo primario. **2004**, 51, 295-302		0
191	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. **2004**, 217, 45-52		72
190	The use of aldosterone receptor blockers in the treatment of hypertension. **2004**, 6, 632-5		2
189	Diuretic-related side effects: development and treatment. **2004**, 6, 532-40		66
188	Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. **2004**, 30, 311-8		11
187	Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. **2004**, 44, 604-10; quiz 610-1		6
186	A patient with concurrent primary hyperaldosteronism and adrenal insufficiency. **2004**, 328, 344-7		1
185	Gynecomastia. **2004**, 104, 72AA-72GG		
184	The role of aldosterone blockers in the management of chronic heart failure. **2005**, 330, 176-83		6
183	The risks and benefits of aldosterone antagonists. **2005**, 2, 65-71		15
182	Antihypertensive therapy: role of aldosterone antagonists. *Current Pharmaceutical Design*, **2005**, 11, 2235-42	3.3	8
181	Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. *Current Pharmaceutical Design*, **2005**, 11, 4161-75	3.3	89
180	Eplerenone: a review of its use in essential hypertension. **2005**, 5, 51-69		24
179	Drug-induced diabetes mellitus. **2005**, 4, 1097-109		26
178	Gynecomastia and hypertension. **2005**, 7, 245-8		13

177	The aldosterone antagonist and facultative diuretic eplerenone: a critical review. **2005**, 16, 3-11	20
176	The aldosterone antagonist and facultative diuretic eplerenone: A critical review. **2005**, 16, 145-153	
175	Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. **2005**, 3, 497-512	0
174	Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?. **2006**, 24, 993-7	25
173	Does eplerenone have a future in the management of hypertension in Europe?. **2006**, 20, 829-32	4
172	[Modern pharmacological aspects of hyperaldosteronism therapy]. **2006**, 47, 953-9	3
171	Adrenal corticosteroids, their receptors and hypertension. **2006**, 67, 871-883	5
170	The significance of cicatricial conjunctivitis in Wegener's granulomatosis. **2006**, 21, 3342-3	2
169	[Normokalemic primary hyperaldosteronism]. **2006**, 131, H24-7	5
168	Primary aldosteronism: diagnostic and treatment strategies. **2006**, 2, 198-208; quiz, 1 p following 230	151
167	Aldosterone antagonists in the treatment of heart failure. **2006**, 63, 49-58	12
166	The pharmacological treatment of primary aldosteronism. **2006**, 7, 563-73	9
165	The risks and benefits of therapy with aldosterone receptor antagonist therapy. **2007**, 2, 71-7	11
164	Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension. **2007**, 10 Suppl 1, 25-31	12
163	Effect of spironolactone on blood pressure in subjects with resistant hypertension. **2007**, 49, 839-45	495
162	Update of diuretics in the treatment of hypertension. **2007**, 14, 154-60	35
161	Aldosterone antagonist therapy in resistant hypertension. **2007**, 25, 747-50	24
160	Stereoselective synthesis of the two major metabolites of spironolactone, 3alpha- and 3beta-hydroxy-7alpha-methylthio-17alpha-pregn-4-ene-21,17-carbolactone. **2007**, 72, 569-72	5

159	Antialdosteronici vecchi e nuovi nel trattamento dell'ipertensione e dello scompenso cardiaco. **2007**, 8, 177-183	
158	Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. **2007**, 8, 309-20	66
157	Mineralocorticoid receptor antagonists. **2007**, 9, 45-52	5
156	Treating resistant hypertension with spironolactone. **2008**, 10, 211-2	
155	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. **2008**, 31, 153-8	149
154	Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. **2008**, 4, 44-52	21
153	Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. **2008**, 93, 3266-81	1231
152	The effects of spironolactone on nephron function in patients with diabetic nephropathy. **2008**, 30, 982-91	13
151	Adrenalectomy improves arterial stiffness in primary aldosteronism. **2008**, 21, 1086-92	68
150	Aldosterone as an independent factor in cerebrovascular damage. **2008**, 30, 785-97	6
149	Adrenal Toxicology. **2008**,	1
148	Nuclear Receptors as Targets in Cardiovascular Diseases. **2008**, 409-429	2
147	The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. **2009**, 15 Suppl 1, 1-20	286
146	Safety and Efficacy of Eplerenone in the Management of Essential Hypertension. **2009**, 1, CMT.S2211	
145	Hyperaldosteronism in pregnancy. **2009**, 3, 123-32	11
144	[Conn's syndrome]. **2009**, 50, 17-26	1
143	Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. **2009**, 68, 634-7	11
142	Aldosteronomas--state of the art. **2009**, 89, 1241-53	24

141	Aldosterone-receptor antagonism in hypertension. **2009**, 27, 680-91	66
140	Spironolactone for hypertension. **2009**,	
139	Spironolactone for hypertension. **2010**, CD008169	29
138	Eplerenone: Selective Aldosterone Antagonist. **2010**, 359-381	
137	Hypertension: spironolactone and resistant hypertension. **2010**, 6, 248-50	3
136	New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. **2010**, 113, 310-4	10
135	[The role of aldosterone in hypertension]. **2010**, 122, 65-74	4
134	. **2010**,	25
133	Efficacy of spironolactone therapy in patients with true resistant hypertension. **2010**, 55, 147-52	189
132	Review article: eplerenone: an underused medication?. **2010**, 15, 318-25	6
131	Endocrine Causes of Hypertension Aldosterone. **2010**, 469-476	
130	A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. **2010**, 285, 29932-40	122
129	Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. **2010**, 56, 831-8	139
128	Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. **2010**, 5, 9	43
127	Novel therapeutic targets for hypertension. **2010**, 7, 431-41	89
126	Treatment of primary aldosteronism. **2010**, 24, 923-32	17
125	The effect of low-dose spironolactone on resistant hypertension. **2010**, 4, 290-4	55
124	Emerging drugs which target the renin-angiotensin-aldosterone system. **2011**, 16, 619-30	23

123	Validation of a therapeutic scheme for the treatment of resistant hypertension. **2011**, 5, 498-504	13
122	Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis. **2011**, 2011, 368140	4
121	Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. **2011**, 7, 353-63	31
120	Diuretics. **2011**, 33, 437-445	
119	SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. **2011**, 115, 346-53	32
118	Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. **2011**, 54, 8616-31	74
117	Treatment of primary aldosteronism: Where are we now?. **2011**, 12, 15-20	9
116	Resistant Hypertension. **2011**, 5, 307-313	
115	Counseling techniques to address male communication characteristics: an application of the extended parallel process model. **2011**, 24, 386-90	2
114	Mineralocorticoid hypertension. **2011**, 15 Suppl 4, S298-312	11
113	Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications. **2012**, 18, 2133-7	37
112	Overview of the renin□ngiotensin□ldosterone system. **2012**, 6-13	
111	A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. **2012**, 59, 934-42	47
110	Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. **2012**, 30, 1656-64	88
109	[Endocrine disease:progress in diagnosis and treatment. Topics: II. Progress in treatment; 6. Renin-angiotensin-aldosterone inhibition in the medical treatment of primary aldosteronism]. **2012**, 101, 1015-20	
108	Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension. **2012**, 14, 732-4	6
107	Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. **2012**, 350, 310-7	110
106	Primary aldosteronism: from bench to bedside. **2012**, 41, 31-9	11

105	Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists. **2013**, 21, 5983-94	26
104	Spironolactone use and the risk of breast and gynecologic cancers. **2013**, 37, 870-5	31
103	Mineralocorticoid receptor antagonists: their use and differentiation in Japan. **2013**, 36, 185-90	13
102	Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. **2013**, 20, 2274-8	33
101	Aldosterone synthase inhibition in humans. **2013**, 28, 36-43	66
100	Diagnosis and management of primary aldosteronism: an updated review. **2013**, 45, 375-83	93
99	A safe and practical method for the preparation of 7□thioether and thioester derivatives of spironolactone. **2013**, 78, 102-7	2
98	Association of smoking with phenotype at diagnosis and vascular interventions in patients with renal artery fibromuscular dysplasia. **2013**, 61, 1227-32	43
97	Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. **2013**, 31, 1948-51	
96	Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. **2013**, 31, 2094-102	94
95	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. **2013**, 31, 2455-61	107
94	Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. **2013**, 31, 3-15	73
93	Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. **2013**, 31, 404-13	17
92	Aldosterone receptor antagonists: current perspectives and therapies. **2013**, 9, 321-31	25
91	WNT/□catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. **2014**, 23, 889-905	130
90	Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. **2014**, 16, 143-50	19
89	Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. **2014**, 16, 414	24
88	Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. **2014**, 4, 1083-119	9

87	-Adrenergic receptor antagonists and gynecomastia. A case series from the Italian spontaneous reporting system and VigiBase(**2014**, 70, 1003-9	4
86	Comparison of agents that affect aldosterone action. **2014**, 34, 285-306	23
85	Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. **2015**, 33, 874-82; discussion 882	28
84	A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE. **2015**, 11, 177-181	
83	DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats. **2015**, 354, 2-9	6
82	Pharmacological treatment of aldosterone excess. **2015**, 154, 120-33	22
81	Outcomes of drug-based and surgical treatments for primary aldosteronism. **2015**, 22, 196-203	17
80	Gynecomastia and drugs: a critical evaluation of the literature. **2015**, 71, 569-78	30
79	Rhesus monkey model for concurrent analyses of in vivo selectivity, pharmacokinetics and pharmacodynamics of aldosterone synthase inhibitors. **2015**, 71, 137-46	9
78	Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. **2015**, 172, R125-9	12
77	Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. **2015**, 17, 542	2
76	Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. **2015**, 17, 540	7
75	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. **2015**, 16, 2283-92	19
74	Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. **2015**, 761, 226-34	62
73	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. **2015**, 20, 283-90	10
72	Spironolactone. **2016**, 472-481	
71	Endocrine Hypertension. **2016**, 556-588	6
70	Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. **2016**, 96, 1327-84	83

69	Primary Aldosteronism: Diagnosis and Management. **2016**, 352, 391-398	13
68	Primary Aldosteronism: A Field on the Move. **2016**, 29-55	1
67	Should All Patients with Resistant Hypertension Receive Spironolactone?. **2016**, 18, 81	6
66	SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism. **2016**, 77, 226-34	11
65	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. **2016**, 101, 1889-916	1240
64	Issues in the Diagnosis and Treatment of Primary Aldosteronism. **2016**, 23, 73-82	
63	Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity. **2017**, 12, 50-65	9
62	30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. **2017**, 234, T125-T140	109
61	Aldosterone a Relevant Factor in the Beginning and Evolution of Arterial Hypertension. **2017**, 30, 468-469	5
60	A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis. **2017**, 96, e8719	12
59	Cardiovascular/Pulmonary Medications and Male Reproduction. **2017**, 1034, 103-130	4
58	Diagnosis and management of primary aldosteronism. **2017**, 61, 305-312	35
57	Gender Differences in the Pathogenesis and Management of Heart Disease. **2018**,	1
56	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. **2018**, 179, R19-R29	57
55	Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit. **2018**, 36, 939-946	8
54	Diagnosis and Management of Primary Aldosteronism. **2018**, 245-260	
53	Secondary Hypertension. **2018**, 126-135	
52	Renin Angiotensin Aldosterone System Blockers. **2018**, 230-241	1

51	Mineralocorticoid Receptors, Neuroinflammation and Hypertensive Encephalopathy. **2019**, 39, 483-492	11
50	[Sexual dysfunction and antihypertensive treatment: Involvement of the different therapeutic classes and what to do about the treatment of hypertension]. **2019**, 48, 1222-1228	0
49	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. **2019**, 50, 345-356	80
48	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. **2019**, 50, 333-344	70
47	[Spironolactone in resistant essential hypertension]. **2019**, 48, 1431-1438	
46	Adrenalectomy Improves the Long-Term Risk of End-Stage Renal Disease and Mortality of Primary Aldosteronism. **2019**, 3, 1110-1126	22
45	Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. **2019**, 285, 126-148	95
44	Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management. **2020**, 28, 84-91	6
43	Treatment of primary hyperaldosteronism. **2020**, 155, 302-308	
42	The drugs that mostly frequently induce gynecomastia: A national case´-´noncase study. **2020**, 75, 225-238	4
41	Pathogenesis and treatment of primary aldosteronism. **2020**, 16, 578-589	17
40	Treatment of primary hyperaldosteronism. **2020**, 155, 302-308	3
39	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. **2020**, 23, 527-533	7
38	Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism. **2021**, 44, 426-434	1
37	Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. **2021**,	0
36	Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology. **2021**, 9,	3
35	Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism. **2021**, 5, bvab144	1
34	Endocrine Hypertension. **2011**, 545-577	10

33	Aldosterone receptor blockade: a therapy resurrected. **2003**, 5, 85-8		4
32	Interfering with mineralocorticoid receptor activation: the past, present, and future. **2014**, 6, 61		6
31	Adverse Effects of Mineralocorticoid Receptor Antagonist Administration. *Current Pharmaceutical Design*, **2018**, 24, 5537-5541	3.3	5
30	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. *Current Pharmaceutical Design*, **2018**, 24, 5508-5516	3.3	4
29	A short review of primary aldosteronism in a question and answer fashion. *Endocrine Regulations*, **2018**, 52, 27-40	1.9	5
28	Use of spironolactone in the treatment of resistant arterial hypertension. *Cor Et Vasa*, **2011**, 53, 343-347	0.3	4
27	Primary Aldosteronism. *Korean Journal of Medicine*, **2012**, 82, 396	0.5	2
26	Management of hypertension in primary aldosteronism. *World Journal of Cardiology*, **2014**, 6, 227-33	2.1	24
25	Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol. *Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia*, **2011**, 155, 143-8	1.7	8
24	Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II. *Cardiovascular Therapy and Prevention (Russian Federation)*, **2021**, 20, 2845	0.9	
23	Adrenal Cortex Hypertension. **2005**, 792-806		
22	Secondary Hypertension: Endocrine Causes. **2007**, 600-612		
21	Primary Hyperaldosteronism. **2009**, 365-377		
20	5.??????????????????????????. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2009**, 40, 51S-52S	0	
19	The treatment of primary hyperaldosteronism. *Problemy Endokrinologii*, **2010**, 56, 41-46	0	2
18	S. **1994**, 545-764		
17	The efficacy and safety of torasemid in the treatment of arterial hypertension in different clinical situations. *Systemic Hypertension*, **2017**, 14, 72-78	1.6	
16	Gender Differences in Cardiovascular Drugs. **2018**, 287-302		

15	Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial. *Acta Cardiologica Sinica*, **2018**, 34, 59-65	1.1	12
14	Diagnosis and treatment of primary aldosteronism. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 876-892	18.1	7
13	Diuretic Agents. **2021**,		
12	How to Explore an Endocrine Cause of Hypertension.. *Journal of Clinical Medicine*, **2022**, 11,	5.1	0
11	Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 798364	5.4	1
10	Development of Polar Organic Mode Chromatographic Method by Polysaccharide-Based Immobilized Chiral Selector and Validation for the Determination of the Enantiopurity of Novel Mineralocorticoid Receptor Antagonist Atropisomer Esaxerenone. *Chromatographia*, 1	2.1	0
9	Management of High Blood Pressure. **2022**, 335-351		
8	Hochdruck und Nebenniere.		
7	Blood Pressure Agents. **2022**, 279-286		
6	Hochdruck und Nebenniere.		
5	Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction. **2022**, 15,		0
4	Personalized Treatment of Patients with Primary Aldosteronism. **2022**,		0
3	Systematic approach to the diagnosis and management of endocrine hypertension. **2023**, 331-368		0
2	Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. **2023**, 12,		0
1	Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. 14,		0